Disease Domain | Count |
---|---|
Infectious Diseases | 6 |
Top 5 Drug Type | Count |
---|---|
Vaccine | 3 |
Prophylactic vaccine | 1 |
Recombinant protein | 1 |
Biological products | 1 |
Target |
Mechanism 50S subunit inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Oct 1969 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date06 Dec 2022 |
Sponsor / Collaborator ![]() [+1] |
Start Date22 Aug 2022 |
Sponsor / Collaborator ![]() [+3] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Malaria vaccine live attenuated (Sanaria) | Malaria, Falciparum More | Phase 2 |
Recombinant Hybrid GMZ-2(Statens Serum Institute) | Malaria, Vivax More | Phase 2 |
PfSPZ-GA1 | Malaria More | Phase 2 |
SPZ (Sanaria) | Malaria More | Phase 1 Clinical |
Ty21a-ETEC | Dysentery, Bacillary More | Preclinical |